We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Human Interferon-Induced Protein Blocks Zika Virus Infection

By LabMedica International staff writers
Posted on 15 Jun 2016
Image: IFITM3 blocks Zika virus infection. When human cells are exposed to Zika virus they are overwhelming infected, as seen by the large number of green cells (left panel). When IFITM3 levels were boosted in these cells, the same amount of virus was prevented from replicating (right panel) (Photo courtesy of Brass Lab, University of Massachusetts Medical School).
Image: IFITM3 blocks Zika virus infection. When human cells are exposed to Zika virus they are overwhelming infected, as seen by the large number of green cells (left panel). When IFITM3 levels were boosted in these cells, the same amount of virus was prevented from replicating (right panel) (Photo courtesy of Brass Lab, University of Massachusetts Medical School).
A team of molecular virologists has shown that the human protein IFITM3 (interferon-induced protein 3) inhibits Zika virus infection early in the viral life cycle and can prevent Zika-virus-induced cell death.

The IFITM family of restriction factors has been found to inhibit the replication of a broad range of viruses, including the closely related flaviruses West Nile virus and dengue virus.

Investigators at the University of Massachusetts Medical School (Worcester, USA) used tools and assays that had been developed for studying IFITM3 in dengue and influenza virus infections to evaluate the effect of this factor on Zika virus.

They reported in the June 3, 2016, online edition of the journal Cell Reports that IFITM3 and the closely related IFITM1 inhibited Zika virus infection early in the viral life cycle. Moreover, IFITM3 was shown to prevent Zika-virus-induced cell death.

"We simply adapted the technology we had developed over the last four years working with dengue, influenza, and other viruses to begin work on Zika virus," said senior author Dr. Abraham Brass, assistant professor of microbiology and physiological systems at the University of Massachusetts Medical School.

"This work represents the first look at how our cells defend themselves against Zika virus' attack," said Dr. Brass. "Our results show that Zika virus has a weakness that we could potentially exploit to prevent or stop infection. A lot of data by us and others in the field has shown that IFITM3 has a big impact on blocking many emerging viruses such as dengue, Zika, and Ebola. Given our recent results with Zika virus, it is now even more important that we work to find out how IFITM3 is blocking these viruses, and use that knowledge to prevent and treat infections."

Related Links:
University of Massachusetts Medical School


Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Gold Member
Hybrid Pipette
SWITCH

Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: MG Tech adds STOMmics Stereo-seq spatial multi-omics technology to its potfolio (photo courtesy of STOmics)

MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition

MGI Tech Co., Ltd. (Shenzhen, China) announced the acquisition of STOmics and CycloneSEQ on March 3, 2026, as part of its “SEQALL+GLI+Omics” strategy. According to the company, the combined portfolio spans... Read more
INTEGRA BIOSCIENCES AG